Italia markets open in 2 hours 43 minutes

Sarepta Therapeutics, Inc. (0L35.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
137,25+4,99 (+3,77%)
Alla chiusura: 05:40PM GMT

Sarepta Therapeutics, Inc.

215 First Street
Suite 415
Cambridge, MA 02142
United States
617 274 4000
https://www.sarepta.com

Settore/i
Settore
Impiegati a tempo pieno1.162

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Douglas S. Ingram Esq.President, CEO & Director1,62MN/D1963
Mr. Ian Michael EstepanExecutive VP & CFO917,53kN/D1976
Dr. Louise R. Rodino-Klapac Ph.D.Executive VP, Chief Scientific Officer and Head of Research & Development1,04MN/D1978
Mr. Ryan E. Brown J.D.Executive VP, General Counsel & Corporate Secretary823,36kN/D1978
Mr. Bilal ArifExecutive VP & Chief Technical Operations OfficerN/DN/D1972
Ms. Francesca T. NolanExecutive Director of Investor Relations and Corporate CommunicationsN/DN/DN/D
Ms. Alison NasisiExecutive VP & Chief People OfficerN/DN/DN/D
Dr. Diane L. Berry Ph.D.Executive VP and Chief of Global Policy & Advocacy OfficerN/DN/DN/D
Mr. Dallan MurrayExecutive VP & Chief Customer OfficerN/DN/DN/D
Mr. Will TiltonSenior VP, Head of Strategy & Chief of StaffN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; and AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program that is under Phase 1/2a clinical trial; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Selecta Biosciences; Hansa Biopharma; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Sarepta Therapeutics, Inc. al 1 febbraio 2024 è 6. I criteri di valutazione fondamentali sono revisione: 6; Consiglio di Amministrazione: 3; diritti degli azionisti: 3; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.